RayThera

Private

#Immunology #Inflammation #Small-Molecule Drug Discovery

RayThera is a San Diego-based private biotech developing small-molecule therapeutics in immunology. Founded in 2023 with a $110M Series A, the company is being acquired by Biogen in a deal worth up to $1B, marking a major exit for the immunology-focused startup.

Company Info

Sector: Biotechnology / Immunology (Small Molecule)

Headquarters: San Diego, California, USA

Founded: 2023

Website: www.raythera.com/

Funding Round: Series A ($110M, April 2025)

Total Funding: $110M reported prior to acquisition

Funding & Investor Relations

Notable Investors

Atlas Venture
RA Capital
BVF Partners
OrbiMed
Surveyor Capital

IPO Outlook / Plans

Acquired by Biogen (June 2026)

Upcoming Milestones & Key Dates

2026-06-17

M&A

Biogen acquisition announced (up to $1B)

2026-Q3

M&A

Expected acquisition close

2027

Regulatory

Lead asset IND filing target

Clinical Development Pipeline

Undisclosed lead immunology asset

Target: Small molecule

Anti-inflammatory (specific indication undisclosed)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Undisclosed second program

Target: Small molecule

Undisclosed immunology indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Exploratory programs

Target: Small molecule

Multiple immunology targets

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Biogen makes up to $1B deal for secretive anti-inflammatory biotech ↗

Biogen announced an up-to-$1B acquisition of RayThera, a secretive anti-inflammatory biotech, marking a major move into immunology diversification beyond the company's neuroscience core.

Leadership Team

Mary Gieson

VP Corporate Operations

Founder team

Scientific founders (small-molecule immunology)

Biogen integration lead

Post-acquisition integration

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →